About Dr. Khan
Arif Khan, MD, is a Board Certified Psychiatrist and Adjunct Professor of Psychiatry at Duke University School of Medicine. He is the President and Principal Investigator at Northwest Clinical Research Center in Bellevue, Washington. Dr. Khan has been conducting clinical trials in the greater Seattle area since 1984 and founded NWCRC in 1995.
Dr. Khan as conducted over 90 clinical trials studying depression, fibromyalgia, and osteoarthritis. His research has been instrumental in the FDA approval of medication such as Cymbalta®, paroxetine, citalopram, duloxetine and vilazadone, just to name a few. A few of his publications on depression are linked below.
Can the placebo treat depression? That depends. Friedman RA. New York Times: June 25th, 2002.
http://www.nytimes.com/2002/06/25/health/behavior-can-the-placebo-treat-depression-that-depends.html
Are placebo controls necessary to test new antidepressants and anxiolytics? Khan A, Khan S, Brown WA. International Journal of Neuropsychopharmacology 5: 193-197, 2002.
Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Khan A, Kolts RL, Thase ME, Krishnan KR, Brown WA. American Journal of Psychiatry, 160(11): 2045-2049, 2004.